Legend Biotech Corporation
LEGN
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatmā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$34.20
Price-4.95%
-$1.78
1Y
Price
Market Cap
$6.325b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-10.3%
EBITDA Margin-17.8%
Net Profit Margin-36.4%
Free Cash Flow Margin-10.3%
EBITDA Margin-17.8%
Net Profit Margin-36.4%
Free Cash Flow MarginRevenue
$1.140b
+10.8%
1y CAGR+64.9%
3y CAGR+84.6%
5y CAGREarnings
-$250.346m
+15.7%
1y CAGR+4.6%
3y CAGR-0.6%
5y CAGREPS
-$1.37
+14.4%
1y CAGR+5.5%
3y CAGR+3.0%
5y CAGRBook Value
$967.730m
$1.597b
Assets$629.020m
Liabilities$389.312m
DebtDebt to Assets
24.4%
-2.2x
Debt to EBITDAFree Cash Flow
-$236.361m
-40.6%
1y CAGR+5.0%
3y CAGR-17.7%
5y CAGRNo items found.
Press Releases
Statements and updates from the company